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Abstract
Background: The objective of this study was to establish 1) the performance of chest X-ray
(CXR) in all suspects of tuberculosis (TB), as well as smear-negative TB suspects and 2) to compare
the cost-effectiveness of the routine diagnostic pathway using Ziehl-Neelsen (ZN) sputum
microscopy followed by CXR if case of negative sputum result (ZN followed by CXR) with an
alternative pathway using CXR as a screening tool (CXR followed by ZN).
Methods: From TB suspects attending a chest clinic in Nairobi, Kenya, three sputum specimens
were examined for ZN and culture (Lowenstein Jensen). Culture was used as gold standard. From
each suspect a CXR was made using a four point scoring system: i: no pathology, ii: pathology not
consistent for TB, iii: pathology consistent for TB and iv: pathology highly consistent for TB. The
combined score i + ii was labeled as "no TB" and the combined score iii + iv was labeled as "TB".
Films were re-read by a reference radiologist. HIV test was performed on those who consented.
Laboratory and CXR costs were used to compare for cost-effectiveness.
Results: Of the 1,389 suspects enrolled, for 998 (72%) data on smear, culture and CXR was
complete. 714 films were re-read, showing a 89% agreement (kappa value = 0.75 s.e.0.037) for the
combined scores "TB" or "no-TB". The sensitivity/specificity of the CXR score "TB" among smear-
negative suspects was 80%/67%. Using chest CXR as a screening tool in all suspects, sensitivity/
specificity of the score "any pathology" was 92%, respectively 63%. The cost per correctly diagnosed
case was for the routine process $8.72, compared to $9.27 using CXR as screening tool. When
costs of treatment were included, CXR followed by ZN became more cost-effective.
Conclusion: The diagnostic pathway ZN followed by CXR was more cost-effective as compared
to CXR followed by ZN. When cost of treatment was also considered CXR followed by ZN
became more cost-effective. The low specificity of chest X-ray remains a subject of concern.
Depending whether CXR was performed on all suspects or on smear-negative suspects only, 22%–
45% of patients labeled as "TB" had a negative culture. The introduction of a well-defined scoring
system, clinical conferences and a system of CXR quality control can contribute to improved
diagnostic performance.
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Background
Since the World Health Organization (WHO) introduced
the DOTS strategy in 1993 for the control of tuberculosis
(TB), Chest X-ray (CXR) has been discouraged for the
diagnosis of TB [1]. As TB is mainly transmitted by spu-
tum smear-positive patients, the DOTS strategy strongly
promotes smear microscopy for the diagnosis of TB
among symptomatic patients, the so-called TB suspects.
Chest X-ray is restricted to diagnosing smear-negative TB
among those suspects whose sputum examination is neg-
ative [2]. Smear microscopy with Ziehl-Neelsen (ZN)
staining is mostly used. Because of its low specificity, if
diagnosis among TB suspects would be based on CXR, this
would lead to a substantial proportion (37%) of over-
diagnosis [3]. But even, when restricting CXR for the diag-
nosis of smear-negative TB among smear-negative sus-
pects, the proportion of over-diagnosis remains high
(23%) [4].
Flowchart of the two diagnostic pathways Figure 1
Flowchart of the two diagnostic pathways.
TB Suspects
n= 998
ZN positive:
“smear-pos. TB”
n=344
“Not consistent
for TB”:
“No TB”
n=332
“Highly consistent for
TB”:
“smear- neg. TB”
n=152
ZN positive:
“smear-pos. TB”
n=311
“No-pathology”:
“No TB”
n=321
3Z N
CXR 3ZN
3 times ZN
negative
n=365
“Highly consistent for
TB”:
”smear-neg. TB”
n=156
3 times ZN
negative
n=654
TB Suspects
n=998
“Any Pathology”
n=677
”Not consistent for
TB”:
“No TB”
n=125
CXR
Pathway 1
ZN followed by CXR
Pathway 2
CXR followed by ZN
“Consistent for TB”:
”smear-neg. TB”
n=84
“Consistent for TB”:
”smear-neg. TB”
n=170BMC Infectious Diseases 2005, 5:111 http://www.biomedcentral.com/1471-2334/5/111
Page 3 of 9
(page number not for citation purposes)
The performance of CXR expressed as sensitivity and spe-
cificity to pick-up culture-positive TB cases depends on the
intensity and the presentation of the disease, which in
turn is influenced by a range of other factors. A major fac-
tor is the HIV status of the patient. In mild immunocom-
promised TB patients, the appearance of the CXR is often
classical with cavitations and upper lobe infiltrates, while
in severe immunocompromised TB patients, the appear-
ance is often atypical [5]. Other factors influencing the
presentation of the disease on the CXR film are delay in
diagnosis and the sex of the patient [6]. Moreover, these
factors are also interdependent of each other [5,6].
Another important factor is the experience and the inter-
pretation skill of the reader [3], making CXR subject to
intra- and inter-reader variation. Studies conducted in the
1950s showed that readers have a tendency to under-read
(21 – 39%) rather than to over-read (2–19%) [3], with
less discrepancy when readers were more experienced. A
study in Japan using Miniature Mass Radiography found
that around 20% of the cases with active TB were missed
[3]. The well- known IUATLD study on X-ray classification
in which 1,100 films were read by 90 experienced physi-
cians and radiologists from 9 countries, found up to 34%
disagreement on the question: "is the film normal?" and
a 28% disagreement on the question: "is there a cavity
present?" [3,7,8]. Finally, the performance of CXR also
depends on the quality of the film, which depends on the
functioning of the CXR machine, the reagents and the
developing process. In addition to the fact that CXR is
unable to distinguish 'smear-positive TB' from 'smear-
negative TB', all above-mentioned factors contribute to
certain degrees of over- and under-diagnosis.
Three steps are recommended as part of the diagnostic
process and is widely practiced in most sub-Saharan coun-
tries. Step one is the identification of TB suspects among
clinic attendees. Step two is the delivery of three sputa for
smear microscopy for the diagnosis of 'smear-positive TB'.
When all three smear results are negative, the TB suspects
enter step three for a CXR for the diagnoses of 'smear-neg-
ative TB'. Although some patients may first start a course
of broad-spectrum antibiotics before entering step three,
the role of CXR for the diagnosis of 'smear-negative TB' is
paramount.
Due to the large number of TB suspects that needs to be
examined by smear microscopy to detect a TB patient, as
is the case in many sub-Saharan cities, adherence to the
prescribed diagnostic procedures is often difficult. This
counts for both the laboratory technicians as well as for
the patients. When these procedures are not strictly fol-
lowed, misclassification and under-diagnosis may occur
[4]. In such settings, an alternative diagnostic pathway can
be used, in which all TB suspects are first subjected to a
CXR leaving smear microscopy only for those suspects
showing pathology on the CXR (CXR followed by ZN).
In this study, we calculated the performance of CXR in
two different patient groups (all TB suspects and the
smear-negative suspects. We also studied the cost-effec-
tiveness of the two diagnostic pathways; 1) the routine
diagnostic pathway of smear microscopy followed by CXR
on those suspects with negative smear results (ZN fol-
lowed by CXR) and 2) the alternative pathway using CXR
as a screening tool by subjecting only those suspects to a
ZN smear who showed any form of pathology on the CXR
(CXR followed by ZN) (Figure 1).
Methods
Between March 2000 and March 2001 TB suspects, aged
15 to 65 years, attending Rhodes Chest Clinic (RCC) in
Nairobi were enrolled into the study. A TB suspect was
defined as somebody presenting at the clinic with a cough
of more than 3 weeks and/or symptoms of haemoptysis.
TB suspects were counseled to obtain informed consent
and to deliver three sputum samples. A spot specimen was
collected at the first attendance day, an early morning spu-
tum was collected the next day at home and a third spot
specimen collected when the patient brought his/her
morning sputum to the clinic. Each sputum specimen was
examined using ZN smear microscopy and Mycobacterial
culture [3]. A slide was labelled ZN positive if one acid fast
bacillus was seen in reading a minimum of at least 100
fields. For culture a volume of 0.25 ml of each decontam-
inated processed sputum specimen was inoculated onto
slants of Lowenstein-Jensen (LJ) medium in culture bot-
tles (Becton Dickenson Microbiology Systems, Cockeys-
ville, MD, USA). The cultures were incubated at 37°C for
8 weeks and examined for growth twice weekly for the first
2 weeks and weekly thereafter until a definitive result was
obtained [9,10]. Accuprobe® (GenProbe, San Diego, CA,
USA) testing identified 98.7% of all culture-positive sam-
ples as M. tuberculosis and a small proportion (1.3%) was
identified as mycobacterium other than M. tuberculosis
(MOTT)[10].
All TB suspects had a CXR. As part of the routine diagnos-
tic procedures of the Kenyan National Leprosy and Tuber-
culosis Programme [11], initially CXR was performed
only on those suspects whose three sputum smear results
were ZN negative. From those who had a positive ZN
smear result a CXR was also taken, however after the diag-
nosis was made. A four point scoring system was intro-
duced to report on the CXR results (i: no pathology, ii:
pathology not consistent for TB, iii: pathology consistent
for TB and iv: pathology highly consistent for TB). A
patient was labeled as 'TB" when the CXR showed pathol-
ogy consistent and/or highly consistent for TB (CXR scoreBMC Infectious Diseases 2005, 5:111 http://www.biomedcentral.com/1471-2334/5/111
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iii and/or iv). Features such as solitary hilar and mediasti-
nal shadows, and diffuse small nodular shadows or pleu-
ral effusion were considered as consistent for TB. Patchy
or nodular shadows, cavitations and calcified shadows
were considered as highly consistent with TB. The radiol-
ogist of RCC established the score. A random selection
was re-scored by a reference radiologist, blinded for the
outcomes of the RCC reader and the ZN smear results.
According to the Kenyan guidelines [11], a patient was
labeled having 'smear-positive TB' if at least one out of
three sputum examination results was ZN positive. (This
is in contrast to other countries where at least two sputum
examinations should be positive). A patient was defined
as 'smear-negative TB' when three sputum smears were ZN
negative and the CXR scored 'TB'. Culture was used as gold
standard. A culture-positive patient having at least one
positive culture result out of three interpretable results
was regarded as a proven TB case. A patient with three neg-
ative culture results was regarded as a non-TB case.
Patients were also counseled for HIV testing on a volun-
tary basis Antibodies to HIV were determined by the Viri-
nostika HIV Uni-Form II plus 0 assay from Organon
Teknika (Boxtel, The Netherlands). Those who did not
want an HIV test remained eligible for study inclusion. For
this study a patient was scored HIV positive, if one test was
positive.
Direct costs were established as described earlier and con-
cerned costs to screen 998 suspects [12]. Labor costs were
calculated from salary scales and routine allowances of
the staff involved. The costs of materials and equipment
for routine screening were included. Only laboratory costs
and cost to establish a CXR were used to compare the cost-
effectiveness of the two diagnostic processes. Cost analysis
was based on processing a maximum of 50 ZN slides and
50 CXRs per day, which was an average performance of
the clinic. Two trained staff performed each procedure. To
follow a full course of treatment only health service costs
were included. Cost-effectiveness analysis was used to
compare the two diagnostic pathways. A correctly diag-
nosed case, defined as a culture-positive patient, was used
as the effect. A sensitivity analysis was made to assess to
what extent change in different TB prevalence environ-
ments would affect cost-effectiveness. Costs are expressed
in US$, using an exchange rate of US$ 1 = 74 KSh (Kenyan
Shillings)
Data were analyzed using Epi info and SPPS statistical
software. Chi-square test was used to compare binary
data. Likelihood ratios were used for the sensitivity analy-
sis. Logistic regression was performed on culture positive
TB patients to assess the impact of HIV on test perform-
ance.
Results
In total 1,389 suspects were enrolled. A result on all three
sputum samples and a CXR was available for 998 (72%)
suspects, forming the study group. Of the remaining 391
(28%) suspects, 169 (12%) missed a third culture result,
mainly due to contamination and 222 (16%) had no CXR
taken, mainly because they did not return to the clinic.
Characteristics of the patients not included were similar to
the study group.
Of the study group, 559 (59%) were culture-positive, 600
(60%) were men and 398 (40%) women with a median
age of 30 years and respectively 27 years (p =< 0.001). For
341 (34%) of the study group a sputum was positive for
ZN, leaving 657 (66%) initially subjected to CXR for the
diagnosis of smear-negative TB. In total, 714 (72%) CXRs
were re-read. When comparing all four scores, the two
readers showed an agreement of 70% (kappa value 0.55,
s.e. 0.023), while for the combined 2-scale score "TB" or
"no-TB" the agreement was 89% (kappa value = 0.75,
s.e.0.037)
The proportion of men who consented to voluntary HIV
testing was 29% as compared to 24 % of the women (p >
Table 1: Results of CXR examination stratified by culture in TB suspects excluding those who were smear-positive on ZN microscopy. 
(N = 657).
Total (N = 657) Culture positive (N = 226) Culture negative (N = 431)
a) Highly consistent for TB 152 (100%) 109 (72%) 43 (28%)
b) Consistent for TB 171 (100%) 71 (42%) 100 (58%)
c) Pathology, but no TB 22 (100%) 6 (27%) 16 (73%)
d) No pathology 312 (100%) 40 (13%) 272 (87%)
" TB"*: (a+b) 323 (100%) 180 (56%) 143 (44%)
" no-TB": (c+d) 334 (100%) 46 (14%) 288 (86%)
* Smear-negative pulmonary TBBMC Infectious Diseases 2005, 5:111 http://www.biomedcentral.com/1471-2334/5/111
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0.05). The seroprevalence was significantly higher among
women than that among men (55.9% versus 33.9%, p =
0.0002).
Among the sputum smear-negative suspects, 49% (323/
657) had a CXR score "TB", of which 180 (56%) were cul-
ture positive (Table 1). Of the 226 culture positive sus-
pects, 80% (180/226) had a CXR result "TB", leaving 20%
(46/226) with a score "no- TB" not picked-up.
When applying CXR on all suspects, the yield in detecting
culture positive suspects with the combined score "Any
pathology" was 92% (515/559), leaving 8 % culture-pos-
itive suspects undetected (Table 2).
Table 3 shows the sensitivity/specificity for each of the
CXR scores in different suspect groups, as well as for the
entire diagnostic processes. Using CXR as a screening tool
on all suspects by using the score "any pathology" the sen-
sitivity was 92%, slightly higher when the score "TB" was
used (91%). Using CXR as a diagnostic tool on smear-neg-
ative suspects, the sensitivity of the score "TB" was 80%.
The sensitivity of the score "Highly consistent for TB"
(48%) was significantly lower as compared to the similar
score on all suspects.
The sensitivity of the routine diagnostic pathway (ZN fol-
lowed by CXR) was 4% higher (93%) than the alternative
pathway (89%) (CXR followed by ZN), leaving 7% and
11% respectively culture-positive cases undetected. As
compared to the alternative pathway, the routine pathway
was more sensitive for both for smear-positive, as well as
for smear-negative TB cases.
Logistic regression was performed to identify whether age,
sex and HIV were risk factors influencing the perform-
ances of CXR. Performing CXR on all suspects, the odds of
having a CXR score "TB" was lower for women (aOR =
0.66, 95% CI 0.51–0.84, p < 0.01) than men, but there
was no association with age or HIV. Restricted to smear-
negative suspects, the result "TB" was associated with HIV,
though this was not statistically significant (aOR 1.72,
95% CI 0.72–3.05, p = 0.064). The sensitivity of the score
"Highly consistent for TB" among HIV- negative suspects
was higher (77%) as compared to HIV-positive suspects
(49%),
Table 2: Results of CXR examination stratified by culture in all TB suspects. (N = 998).
Total (N = 998) Culture positive (N = 559) Culture negative (N = 439)
a) Highly consistent for TB 423 (100%) 379 (90%) 44 (10%)
b) Consistent for TB 229 (100%) 127 (55%) 102 (45%)
c) Pathology, but no TB 27 (100%) 9 (33%) 18 (67%)
d) No pathology 319 (100%) 44 (14%) 275 (86%)
"any pathology"(a+b+c) 679 (100%) 515 (76%) 164 (24%)
" no-TB": (c+d) 364(100%) 53 (15%) 293 (85%)
Table 3: CXR performance on all suspects and on suspects excluding those who were ZN-positive. Culture (patient based) used as gold 
standard (95% confidence interval)
Score of the reader Sensitivity Specificity PPV NPV
CXR on all suspects (n = 998)
a) Highly consistent for TB 68 (64–72) 90 (87–93) 0.90 (0.87–0.93) 0.69 (0.65–0.72)
b) Consistent for TB 23 (19–26) 77 (73–80) 0.55 (0.49–0.62) 0.44 (0.40–0.47)
c) Pathology, but no TB 2 (0–3) 96 (94–98) 0.33 (0.16–0.51) 0.43 (0.40–0.46)
"TB" (a+b) 91 (88–93) 67 (62–71) 0.78 (0.74–0.81) 0.84 (0.81–.088)
"any pathology" (a+b+c) 92 (90–94) 63 (58–67) 0.76 (0.73–0.79) 0.86 (0.82–0.90)
CXR on suspects excluding those who were ZN positive (n = 657)
a) Highly consistent for TB 48 (42–55) 90 (87–93) 0.72 (0.65–0.79) 0.77 (0.73–0.81)
b) Consistent for TB 31 (25–37) 77 (73–81) 0.42 (0.34–0.49) 0.68 (0.83–0.90)
c) Pathology but no TB 3 (1–5) 96 (95–98) 0.27 (0.9–0.46) 0.65 (0.62–0.69)
"TB" (a+b) 80 (74–85) 67 (62–71) 0.56 (0.50–0.61) 0.86 (0.83–0.90)
The entire diagnostic process (n = 998)
ZN followed by CXR 93 (91–95) 62 (57–67) 0.76 (0.72–0.79) 0.87 (0.83–0.91)
CXR followed by ZN 89 (86–91) 97(84–90) 0.90 (0.87–0.92) 0.86 (0.83–0.89)BMC Infectious Diseases 2005, 5:111 http://www.biomedcentral.com/1471-2334/5/111
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As earlier described [6], the sensitivity of the score "TB"
among smear-negative suspects was higher for men (82%)
than for women (77%). The specificity was more or less
similar (66% versus 68%), and improved considerably
when using the score "highly consistent with TB" (88%
and 93%, respectively). Culture-positive men harbor
more cavities than women (62% versus 50%) and also the
average number of cavities among men (2.0) was signifi-
cantly higher (p = 0.032) as compared to women (1.6).
Table 4 shows results of the two diagnostic pathways
including the costs and cost-effectiveness to examine 998
TB suspects. The routine process detected 335 smear-pos-
itive TB cases, 9% more as compared to the alternative
process. The cost-effectiveness per correctly diagnosed
case for the routine process was slightly better (US$8.72
and US$9.27) however, when treatment costs were con-
sidered, including costs of treatment of those falsely diag-
nosed, the alternative pathway was more cost effective
(US$ 137 versus US$ 158).
Figure 2 shows a sensitivity analysis comparing the cost-
effectiveness of the two diagnostic pathways, including
costs of treatment for different proportions (prevalence)
of culture-positive cases among all suspects. In settings
with a low TB prevalence, CXR used as a screening tool
was more cost-effective, while in settings with a TB preva-
lence of more then 40% the cost-effectiveness of both
diagnostic processes was almost equal.
Figure 3a and 3b show the probability of a patient having
TB using ZN microscopy and CXR in settings with differ-
ent TB prevalence. A positive ZN smear result was the best
test to predict a culture-positive case; while the CXR score
'No pathology' was the best test to rule-out TB.
Discussion
Many studies indicate that CXR is unreliable for the diag-
nosis of TB [3]. In contrast to other studies [3], we found
little difference between the reader at RCC and the refer-
ence reader. Our study showed that the performance of
CXR expressed as sensitivity and specificity in picking-up
culture positive TB patients, differed among different
patient groups. When cavities are present, which is more
commonly seen in far-developed smear-positive TB, the
interpretation of the film may be easier, resulting in a
higher sensitivity and specificity. This clarifies why for
example, the sensitivity of the score "Highly consistent for
TB" in all suspects was 68%, while the same score was
only 48% among the smear-negative suspects. Cavities are
also less pronounced among HIV-positive TB cases, which
clarifies why among these groups the sensitivity of CXR
was reduced as well, an observation consistent with a
study conducted in Spain where a considerable number of
Table 4: Results of the two diagnostic pathways including costs* and cost-effectiveness in US$. (N = 998)
ZN followed by CXR (n = 998). CXR followed by ZN (n = 998)
Number of culture positive suspects 559 559
Number of patient put on treatment 666 551
Number Culture pos. patient put on treatment 514 496
C+/ZN+ patients put on treatment 335 308
C+/ZN- patient put on treatment 179 188
Number Culture neg. patients put on treatment (Over diagnosis) 152 56
Number Culture pos. patients not put on treatment (Under diagnosis) 45 63
Laboratory service
Labour costs $973 $973
Investment costs $135 $135
Running costs $1,706 $1,151
Total laboratory costs $2,814 $2,259
X-ray service
Labour costs 154 $154
Investment costs 237 $237
Running costs 1,278 $1,946
Total CXR service costs 1,669 $2,337
Total diagnostic costs $4,483 $4,596
Cost per correctly diagnosed patient $8.72 $9.27
Total treatment costs ** $76,565 $63,422
Diagnostic costs + treatment costs $81,048 $68,018
Cost per correct diagnosed patient including costs of treatment. $158 $137
* costs only include health service costs
** costs for health service to treat a patient: $115BMC Infectious Diseases 2005, 5:111 http://www.biomedcentral.com/1471-2334/5/111
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HIV positive TB patients had a normal CXR [13]. For sim-
ilar reasons, the sensitivity among women was found
lower as compared to men [6].
The presentation of TB, and consequently the perform-
ance of the CXR reading, is also influenced by delay in
accessing diagnosis with longer delays associated with
high numbers of cavities. Such findings were consistent
with a study in Canada, showing over a 10 year period, an
increase in normal CXRs from 1% to 10% among proven
TB cases, which was associated with earlier diagnosis [14]
The low specificity of CXR remains a subject of concern.
When the CXR was labeled as "TB", comprising the com-
bined score "Highly consistent for TB" and "Consistent
for TB", the specificity was low (67%). As a consequence,
the number of patients labeled as having TB using CXR
with a negative culture that were placed treatment was
rather high: 22% among all suspects and 45% among
smear-negative suspects.
The challenge is to increase the specificity of CXR and
diminish the proportion of over-diagnosis of smear-nega-
tive cases. The introduction of the four point scoring sys-
tem, using only the score "Highly consistent for TB" for
diagnosing TB and starting a course of broad-spectrum
antibiotics on those suspects with a score "Consistent for
TB" may improve performance. By doing so, we found
that over-diagnosis could be reduced up to 67%, while
only 8% fewer culture positive cases would start immedi-
ate treatment.
Regarding diagnosis of smear-negative TB, the clinician
often only relies on the CXR result. The radiologist in turn
usually has little or no information about the patient and
in case of doubt may tend to give a positive result. More-
over, although the interpretation of CXR is more compli-
cated than that of smear examination, quality control is
hardly practiced for CXR.
The global DOTS strategy advocates that diagnosis is
based on smear microscopy and restricts CXR only for the
detection of "smear-negative TB cases". Our study sup-
ports this strategy. The routine diagnostic process (ZN fol-
lowed by CXR) detected 9% more culture and 9% more
smear-positive TB cases as compared to the alternative
process (CXR followed by ZN).
When dealing with many TB suspects, the alternative
pathway using CXR as a screening tool is often considered
as being cost-effective [15]. When only direct costs of lab-
oratory and CXR were included, we found the routine
diagnostic process is more cost effective. One should how-
ever take into account that the high numbers of patients
over-diagnosed, and who are falsely put on treatment,
also implies other costs. When treatment costs of all
A: Predictive values of ZN microscopy and the CXR scores:  "Highly consistent for TB" and "Consistent for TB" for having  a positive culture result for M. tuberculosis Figure 3
A: Predictive values of ZN microscopy and the CXR scores: 
"Highly consistent for TB" and "Consistent for TB" for having 
a positive culture result for M. tuberculosis. B: Predictive val-
ues of ZN microscopy (three negative results), CXR score 
"No pathology" to exclude culture-positive TB.
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patients were included in the analysis, including the treat-
ment of those culture-negative patients, the cost-effective-
ness of the alternative process became slightly better.
Emphasis to reduce the falsely diagnosed patients is there-
fore important.
The prevalence of culture-positive TB cases among the
study group was rather high (59%) and may be biased by
the proportion of suspects (16%) who did not return to
the clinic for a CXR and were not included in the study
population, and who all were culture-negative. In the sen-
sitivity analysis (including treatment costs) adjusting for
the prevalence of TB, the alternative pathway remained
more cost-effective, but became more pronounced in set-
tings with TB prevalence lower than 30%, as for example
is the case in total population prevalence surveys.
In addition to diagnosis, CXR play also a role in HIV/TB
combined programs. More countries are implementing
Isoniazid preventive therapy for HIV infected persons to
reduce the development of TB [16]. But before starting a
course of Isoniazid one should rule out active TB.
Although a study performed in Botswana suggested other-
wise [17], we found that the CXR score "No pathology"
with a certainty of over 90% rules out active TB.
Conclusion
In our study, the routine diagnostic pathway (ZN fol-
lowed by CXR) identified a higher number of smear-pos-
itive cases as compared to the alternative process (CXR
followed by ZN) and was also more cost-effective. The low
specificity of CXR remains a subject of concern. Depend-
ing on the group of patients, 22%–45% of cases with a
CXR result "TB" and consequently put on treatment, had
a negative culture.
From the findings of the study, we believe that the intro-
duction of a clearly defined four point scoring system for
CXR for the interpretation of CXR may well improve the
diagnostic performance. Consequently those patients
with a score "Highly consistent for TB" can start directly
anti-TB treatment, while those patients with a score "Con-
sistent for TB" can be considered for a course of broad
spectrum antibiotics with appropriate follow-up.
Being a function of many factors, the performance of CXR
could also improve when the radiologist, through clinical
conferences, would know the underlying information of
the patients, such as treatment history, age or HIV status.
Moreover, being so important members of the diagnostic
team, radiologists should be included in NTP training
programs. Finally, until we have new diagnostic tests
available for field use, we need to ensure not only the
quality of smear microscopy, but also the quality of CXR.
The latter could be improved through the introduction of
quality systems.
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